Guardant Health (GH) Saham Harga
Guardant Health Harga
Selama 9 tahun terakhir pendapatan Guardant Health tumbuh 52,3% per tahun, mencapai 978,12 Juta. USD. Bagi Guardant Health, margin bersih sebesar -42,6% naik dibanding -109,3% beberapa tahun lalu. Target harga konsensus 12 bulan untuk Guardant Health adalah 195,00 USD, sekitar di atas harga saat ini 29,3%. Dari 36 analis, 33 merekomendasikan beli — konsensus keseluruhan Beli.
Harga saham Guardant Health
Akses data ini lewat Eulerpool API
100.000 permintaan/bulan gratis · tanpa kartu
Model bisnis dan analisis saham Guardant Health
Pertanyaan yang sering diajukan tentang saham Guardant Health
The main competitors of Guardant Health Inc in the market include companies such as Foundation Medicine, Exact Sciences Corporation, and Illumina Inc.
The business model of Guardant Health Inc. revolves around precision oncology and liquid biopsy. As a leading precision oncology company, Guardant Health develops and commercializes blood tests that can detect and monitor cancer. By analyzing the genetic alterations in circulating tumor DNA, Guardant Health enables oncologists to make more informed treatment decisions for their patients. The company's comprehensive liquid biopsy platform, including their flagship product Guardant360, provides a non-invasive alternative to traditional tissue biopsies. With their commitment to advancing cancer care, Guardant Health Inc. aims to improve patient outcomes through their innovative molecular diagnostics and therapeutic development solutions.
Guardant Health Inc is primarily active in the healthcare industry.
Guardant Health Inc. is a leading precision oncology company specializing in blood-based cancer tests. Founded in 2012, Guardant Health has rapidly grown to become a prominent player in the field of liquid biopsy. The company's breakthrough technology, Guardant360, enables comprehensive genomic profiling of solid tumors through a simple blood draw, facilitating personalized treatment decisions for cancer patients. With an extensive database of over 120,000 patients, Guardant Health Inc. is revolutionizing cancer diagnostics and therapy selection. Guardant Health is committed to advancing precision oncology and improving patient outcomes through its innovative genomic testing solutions.
Some significant milestones achieved by Guardant Health Inc include the successful completion of their initial public offering (IPO) in October 2018, generating over $235 million in funding. Additionally, the company's liquid biopsy test, Guardant360, received breakthrough device designation from the U.S. FDA in 2018, highlighting its potential impact in cancer diagnostics. Guardant Health Inc also expanded its global presence by establishing partnerships with several pharmaceutical companies and collaborating with research institutions. These achievements demonstrate Guardant Health Inc's growth as a leader in precision oncology, offering innovative solutions and advancing cancer care.
Guardant Health Inc is primarily present in the United States.
Guardant Health Inc represents values of innovation, precision, and compassion in the field of comprehensive cancer care. As a leading precision oncology company, Guardant Health is committed to transforming cancer treatment through advanced diagnostics and therapeutics. With their liquid biopsy technology, they aim to provide personalized and non-invasive genomic profiling, aiding in early cancer detection and treatment decisions. Guardant Health's corporate philosophy revolves around collaboration and empowerment, as they strive to improve patient outcomes and ease the burden of cancer. By combining cutting-edge technology with compassionate care, Guardant Health Inc epitomizes a commitment to revolutionizing cancer care for a better future.
Analis saat ini menetapkan target harga rata-rata 188,80 USD untuk saham Guardant Health (median: 195,00 USD), yaitu +25,1 % terhadap harga terbaru. Konsensus didasarkan pada 36 peringkat analis.
36 analis saat ini menilai saham Guardant Health: 33 merekomendasikan beli, 3 tahan, dan 0 jual. Untuk 2026, analis memperkirakan Guardant Health menghasilkan pendapatan 1,36 miliar USD dan laba per saham -3,25 USD.
Dengan kurs saat ini, saham Guardant Health diperdagangkan pada 135,15 EUR (150,87 USD).
Saham Guardant Health (GH) tercatat di 5 bursa, termasuk: NASDAQ (GH), XETRA (5GH.DE), Frankfurt (5GH.F), München (5GH.MU), Düsseldorf (5GH.DU).
Guardant Health Inc. is a leading company in the field of liquid biopsy and cancer early detection. The company offers innovative solutions and technologies for cancer prevention, diagnosis, and therapy. Guardant Health has two different business units: Guardant360 and GuardantOMNI. Both divisions differ in their target audience and product portfolio. Guardant360 is a blood test that captures the DNA profile of tumor cells, thereby identifying the genetic fingerprint of cancer cells. This allows for more precise and faster diagnosis. The technology of Guardant360 is used by doctors and oncologists to analyze the genetic profiles of tumor cells in real-time and develop the best possible therapy for the patient. GuardantOMNI is a comprehensive cancer genomic test that covers over 500 genes, enabling an accurate diagnosis. GuardantOMNI is used by pharmaceutical companies to develop personalized therapies and drugs. Guardant Health is committed to advancing precision medicine in the field of cancer diagnostics and therapy. By using liquid biopsy technologies, doctors and oncologists can make accurate diagnoses and offer targeted therapy. Guardant Health has also partnered with renowned pharmaceutical companies such as Merck, Bristol-Myers Squibb, and Amgen to develop personalized therapies. In addition, the company has conducted its own clinical study on cancer early detection, and further studies are planned. The business model of Guardant Health is based on selling its products and solutions to medical facilities such as hospitals, laboratories, and oncologists. The company also generates revenue through partnerships with pharmaceutical companies and participation in clinical trials. Overall, Guardant Health is a company with a promising business model based on the use of liquid biopsy technologies. The company aims to revolutionize cancer diagnostics and therapy and offer personalized medicine. The wide portfolio of solutions and products from Guardant Health allows it to cater to the needs of doctors, oncologists, and pharmaceutical companies.
Pendapatan diperkirakan dari Guardant Health adalah 1,36 miliar USD. Angka ini didasarkan pada data keuangan terkini dan mencerminkan kinerja bisnis perusahaan.
Laba diperkirakan dari Guardant Health adalah -418,42 Juta. USD. Laba bersih mencerminkan profitabilitas perusahaan setelah mengurangi semua biaya.
Rasio harga-terhadap-pendapatan (PER) Guardant Health saat ini adalah -46,39. PER membandingkan harga saham saat ini dengan laba per saham dan membantu investor menilai valuasi saham Guardant Health.
Rasio harga-terhadap-penjualan (PSR) Guardant Health saat ini adalah 14,30. PSR membandingkan kapitalisasi pasar dengan pendapatan tahunan dan berfungsi sebagai metrik valuasi untuk saham Guardant Health.
Skor Kualitas AlleAktien untuk Guardant Health adalah 5/10.
ISIN dari Guardant Health adalah US40131M1099. ISIN (International Securities Identification Number) adalah identifikasi unik global untuk sekuritas.
WKN dari Guardant Health adalah A2N5RY. WKN (Wertpapierkennnummer) adalah kode identifikasi sekuritas Jerman enam digit.
Ticker dari Guardant Health adalah GH. Simbol ticker digunakan untuk memperdagangkan saham Guardant Health di bursa saham.
Saham Guardant Health
Kelompok Peer Guardant Health
Guardant Health Ticker
Guardant Health FIGI
Semua metrik fundamental dan analisis mendalam Guardant Health
Analisis saham kami untuk saham Guardant Health mencakup kalkulasi keuangan penting seperti pendapatan, keuntungan, P/E ratio (P/E), P/S ratio (P/S), EBIT, serta informasi tentang dividen. Selain itu, kami juga mengamati aspek-aspek seperti saham, kapitalisasi pasar, utang, ekuitas, dan kewajiban dari Guardant Health. Jika Anda mencari informasi lebih rinci tentang topik-topik ini, kami menawarkan analisis terperinci di subhalaman kami.